Blueprint Medicines (BPMC) PT Lowered to $151 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Price: $129.46 --0%
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 56
Rating Summary:
11 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 24 | New: 56
Join SI Premium – FREE
Wells Fargo analyst Derek Archila lowered the price target on Blueprint Medicines (NASDAQ: BPMC) to $151.00 (from $153.00) while maintaining a Overweight rating.
You May Also Be Interested In
- B&M European Value Retail SA (BME:LN) (BMRRY) PT Raised to GBP3.40 at Berenberg
- Boston Beer Company (SAM) PT Raised to $200 at Morgan Stanley
- NAVER Corp. (035420:KS) (NHNCF) PT Lowered to KRW240,000 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
